Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash & Equivalents (2018 - 2021)

Historic Cash & Equivalents for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $46.6 million.

  • Black Diamond Therapeutics' Cash & Equivalents fell 1707.21% to $46.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $46.6 million, marking a year-over-year decrease of 1707.21%. This contributed to the annual value of $34.6 million for FY2020, which is 7762.6% down from last year.
  • As of Q3 2021, Black Diamond Therapeutics' Cash & Equivalents stood at $46.6 million, which was down 1707.21% from $37.3 million recorded in Q2 2021.
  • Over the past 5 years, Black Diamond Therapeutics' Cash & Equivalents peaked at $357.2 million during Q1 2020, and registered a low of $14.1 million during Q1 2021.
  • Its 4-year average for Cash & Equivalents is $81.6 million, with a median of $49.1 million in 2018.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Cash & Equivalents surged by 69878.12% in 2020, and later plummeted by 9605.11% in 2021.
  • Black Diamond Therapeutics' Cash & Equivalents (Quarter) stood at $51.7 million in 2018, then surged by 199.39% to $154.7 million in 2019, then tumbled by 77.63% to $34.6 million in 2020, then surged by 34.67% to $46.6 million in 2021.
  • Its Cash & Equivalents was $46.6 million in Q3 2021, compared to $37.3 million in Q2 2021 and $14.1 million in Q1 2021.